Skip to main content

Advertisement

Table 2 Pulmonary function, SUVmax and TLuG at baseline and after 26 weeks infliximab treatment, n = 27; mean ± SD

From: Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

  Baseline After 26 weeks infliximab Change p value
FVC (% predicted) 75.1 ± 18.4 79.7 ± 19.9 + 4.6 ± 8.4 0.009
FEV1 (% predicted) 58.6 ± 17.9 63.6 ± 20.5 + 5.1 ± 6.8 0.001
DLCOc (% predicted)a 55.5 ± 17.9 57.9 ± 16.9 + 2.4 ± 6.8 0.100
SUVmax 8.2 ± 4.7 3.1 ± 2.9 − 5.1 ± 5.1 < 0.001
TLuG 5395 ± 3216 2641 ± 952 − 2755 ± 3064 < 0.001
  1. FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCOc diffusing capacity of the lung for carbon monoxide corrected for haemoglobin, SUVmax maximum standardized uptake value, TLuG total lung glycolysis
  2. aThree missing values